Other Information
−Removed: During the three months ended September 28, 2024, no director or officer of the Company (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended) adopted , terminated or modified a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
−Removed: Carl Russo, Chairman of the Board of Directors of the Company, is Trustee of The Crescentico Trust U/A DTD 09/06/1999.
−Removed: On May 3, 2024, The Crescentico Trust adopted a Rule 10b5-1 trading arrangement (the “10b5-1 Plan”) that is intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
−Removed: The 10b5-1 Plan allows for the sale of up to 100,000 shares of Common Stock, at market prices, commencing August 2024, and continuing until April 2025.
+Added: During the three months ended March 29, 2025, no director or officer of the Company (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended) adopted , terminated or modified a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K, except as follows:
+Added: On February 7, 2025 , Cory Sindelar , Chief Financial Officer of the Company, adopted a Rule 10b5-1 trading arrangement (the “Sindelar 10b5-1 Plan”) that is intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
+Added: The Sindelar 10b5-1 Plan allows for the contemporaneous exercise of options and sale of up to 130,000
+Added: shares of Common Stock, at specific market prices, commencing on May 9, 2025, and continuing until all such options are exercised and the underlying shares are sold, or June 30, 2026 , whichever comes first.
+Added: On February 28, 2025 , Michael Weening , Director, President and Chief Executive Officer of the Company, adopted a Rule 10b5-1 trading arrangement (the “Weening 10b5-1 Plan”) that is intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
+Added: The Weening 10b5-1 Plan allows for the contemporaneous exercise of options and sale of up to 974,000 shares of Common Stock, at specific market prices, commencing on May 30, 2025, and continuing until all such options are exercised and the underlying shares are sold, or February 28, 2026 , whichever comes first.
Number Description
7 unchanged sentences
333-163252) and incorporated by reference).
+Added: 10.1* Calix, Inc.
+Added: Non-Employee Director Cash Compensation Policy, as amended March 21, 2025.
+Added: 10.2* Calix, Inc.
+Added: Non-Employee Director Equity Compensation Policy, as amended March 21, 2025.
+Added: 10.3* Calix, Inc.
+Added: Non-Employee Director Restricted Stock Award Agreement.
31.1 Certification of Chief Executive Officer of Calix, Inc.
11 unchanged sentences
101.PRE XBRL Taxonomy Extension Presentation Linkbase Document
+Added: * Indicates management contract or compensatory plan or arrangement.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
−Removed: October 29, 2024 By:
+Added: April 22, 2025 By:
/s/ Michael Weening
2 unchanged sentences
(Principal Executive Officer)
−Removed: October 29, 2024 By:
+Added: April 22, 2025 By:
/s/ Cory Sindelar
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.